Leerink Partnrs Has Positive Forecast for TWST Q1 Earnings

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Analysts at Leerink Partnrs upped their Q1 2025 EPS estimates for shares of Twist Bioscience in a research note issued to investors on Monday, November 18th. Leerink Partnrs analyst P. Souda now anticipates that the company will post earnings per share of ($0.65) for the quarter, up from their prior forecast of ($0.71). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.56) per share. Leerink Partnrs also issued estimates for Twist Bioscience's Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.34) EPS and FY2026 earnings at ($1.84) EPS.

Several other research firms have also recently weighed in on TWST. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday. Leerink Partners increased their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Barclays cut their price objective on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Tuesday. Scotiabank raised their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research report on Tuesday. Finally, Evercore ISI upped their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.78.

Twist Bioscience Price Performance

TWST stock traded up $1.11 during trading on Thursday, hitting $42.22. 526,378 shares of the stock traded hands, compared to its average volume of 950,996. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -11.42 and a beta of 1.78. The firm's 50 day moving average is $43.93 and its two-hundred day moving average is $46.15. Twist Bioscience has a 1 year low of $23.07 and a 1 year high of $60.90.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Signaturefd LLC raised its stake in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after buying an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new stake in Twist Bioscience during the 2nd quarter valued at about $43,000. Blue Trust Inc. raised its holdings in shares of Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock worth $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after purchasing an additional 381 shares during the period.

Insider Buying and Selling

In related news, SVP Paula Green sold 1,057 shares of the stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total value of $43,928.92. Following the sale, the senior vice president now directly owns 121,013 shares of the company's stock, valued at $5,029,300.28. This represents a 0.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Robert F. Werner sold 1,448 shares of the business's stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the sale, the chief accounting officer now directly owns 45,620 shares of the company's stock, valued at $2,034,652. This represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 98,118 shares of company stock valued at $4,391,151. Company insiders own 3.92% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.